Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating Expenses:
Research and development	$ 1,701,253	$ 3,187,024	$ 6,086,103	$ 11,190,939
General and administrative	2,061,553	2,942,877	7,104,567	9,081,806
Total operating expenses	3,762,806	6,129,901	13,190,670	20,272,745
Operating loss	(3,762,806)	(6,129,901)	(13,190,670)	(20,272,745)
Other income (expense):
Other income (expense), net	213,769	176,855	584,961	137,288
Interest expense	(187)	(8,687)	(5,148)	(372,099)
Total other income (expense), net	213,582	168,168	579,813	(234,811)
Loss from continuing operations before benefit from income taxes and noncontrolling interests	(3,549,224)	(5,961,733)	(12,610,857)	(20,507,556)
Benefit from income taxes	0	(2,413,951)	0	(8,301,494)
Net loss from continuing operations	(3,549,224)	(3,547,782)	(12,610,857)	(12,206,062)
Discontinued operations - net of taxes	0	0	0	37,329,963
Net (loss) income	(3,549,224)	(3,547,782)	(12,610,857)	25,123,901
Less - net income (loss) from continuing operations attributable to noncontrolling interests	972	(119,342)	(1,711)	(149,509)
Less - net loss from discontinued operations attributable to noncontrolling interests	0	0	0	(568,156)
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	(3,550,196)	(3,428,440)	(12,609,146)	25,841,566
Amounts attributable to Caladrius Biosciences, Inc. common stockholders:
Loss from continuing operations	(3,550,196)	(3,428,440)	(12,609,146)	(12,056,553)
Discontinued operations - net of taxes	0	0	0	37,898,119
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	$ (3,550,196)	$ (3,428,440)	$ (12,609,146)	$ 25,841,566
Basic and diluted (loss) income per share
Continuing operations (in usd per share)	$ (0.36)	$ (0.38)	$ (1.31)	$ (1.37)
Discontinued operations (in usd per share)	0.00	0.00	0.00	4.30
Caladrius Biosciences, Inc. common stockholders (in usd per share)	$ (0.36)	$ (0.38)	$ (1.31)	$ 2.94
Weighted average common shares outstanding:
Basic and diluted shares	9,744,680	9,093,880	9,633,603	8,803,784